Sign Up
Ready to replace complexity with clarity?
Answer your real world compliance questions (limited time) and save thousands in legal fees and avoided fines.
Automate Compliance TodayUS states A to Z: marijuana, THCA, delta-8, delta-9, delta-10, HHC
State-by-state mapMost read countries: marijuana, CBD and hemp status
All countries on the globeSubstances: status in every state for each one
Compare all substancesFederal hemp redefinition: P.L. 119-103, div. B, sec. 2019
Nov 12, 2026
Applies only to cannabinoids the plant cannot naturally produce.
Dec 11, 2026
The total-THC test, the 0.4 mg per container cap and the exclusion of converted cannabinoids start.
Latest regulatory actions, updated daily
All regulatory actionsHeadlines and the first four sentences are free. Full write-ups, impact reasoning and the archive are for members.
Member · $99/mo
Every rule change, the day it is made.
The price will rise. Join now and $99 a month stays your rate for life.
Become a memberOr read free: every action opens 30 days after it is published. Sign in with email
By topic
Licensing and permitsPackaging and labelingLab testing and QARetail complianceAdvertising and marketingBanking and paymentsTaxesShipping and logisticsTravel and transportLitigationSOPsFor your role
Regulators and agenciesBrands and operatorsRetailers and smoke shopsCultivatorsProcessorsLawyers and complianceInvestorsConsumers and travelersThe Regulator Brief · newsletter
Every rule change that matters, every Monday.
Free: the Monday brief, and every action 30 days after it is published.
Members: the paid weekly, daily alerts and every write-up.
Read by regulators, operators, lawyers and founders.
Cannabis lawyers
Licensed by state. Listings are not endorsements.
By state
Software and services
Compared by fit, never ranked.
Categories
For companies and firms
Be the listing operators and regulators find.
Software and services
Verified, $49/mo: domain-verified badge, your website link, a quote.
Featured, from $399/mo: labeled Featured in your category, monthly release notes.
Lawyers and firms
Claimed, $75/yr: Claimed badge and your firm's website link.
Featured, $199/mo: labeled Featured on your profile.
Claim your companyClaim a lawyer listingPlacements, flat monthly fee
State and country page sponsorshipsExclusive slot on a legality page and its postsRegulator Brief sponsorshipPresenting sponsor or mid-issue banner, free editionMember brief sponsor slotThe paid weekly, read by members onlyFeatured directory placementLabeled Featured in a software categoryCategory sponsorshipOwn one directory category across the sitePaid guest postsLabeled Paid guest post, sponsored linksWrite and partner
Pitch a paid guest postRead guest postsBecome an affiliateSend a tip or correctionContact the teamWho reads it
Regulators at federal, state and county agencies, plus the operators, lawyers and founders they regulate.
Get the media kitSee open placementsSubstances
US states, map and A to ZCountriesFederal hemp 2026: Nov 12 and Dec 11Compound index, every stateTravelling with cannabis or hempMembers get the daily alert email and every full write-up the morning it is published. Every action is free to read 30 days later.
For your role
All news and analysisGuidesAnalysisFAQsTemplates and SOPsCourt filing recapsNews by state and countrySoftware and services: Verified $49/mo, Featured from $399/mo. Lawyers and firms: Claimed $75/yr, Featured $199/mo. Listings are not endorsements.
Regulatory journalism, not legal advice. How we report

The U.S. Food and Drug Administration’s Human Foods Program (HFP) 2025 guidance agenda was released in mid-2025, shaping compliance priorities across the food and dietary supplement sectors—including those involving cannabinoids like CBD, CBN, and CBG. While the agenda does not specifically call out cannabinoids, several topics hold significant implications for brands formulating foods and supplements with hemp-derived ingredients. Additionally, the FDA’s move to integrate hemp cannabinoids into its adverse event reporting (AER) systems underscores expanded post-market scrutiny for consumer safety and risk.
The 2025 HFP guidance agenda sets out the FDA’s regulatory priorities and the types of draft guidance it plans to release or update. Key topics this year relate directly to the frameworks and tools likely to be applied to CBD and cannabinoid-infused products, even in the absence of explicit CBD rulemaking.
A major development for 2025 is the FDA’s inclusion of hemp-derived cannabinoids—such as CBD, CBN, and CBG—in its Adverse Event Reporting (AER) portals (source). Health care professionals, consumers, and manufacturers can now select cannabinoid product types directly when filing adverse event or complaint reports. This change signals:
Based on the 2025 HFP guidance agenda and the FDA’s recent actions, the most relevant areas of near-term compliance and enforcement pressure for the cannabinoid sector include:
In light of 2025’s agenda, compliance-minded brands should:
The FDA’s 2025 Human Foods Program agenda is notable for what it signals more than what it mandates. For cannabinoid brands, it marks a continued migration of compliance expectations from the dietary supplement sector into the food and beverage world, with new enforcement levers poised to activate as hemp cannabinoids take center stage in the AER system.
Staying ahead means engaging now—ensuring your products withstand scrutiny on labeling, ingredient sourcing, color/additive approvals, and post-market complaint monitoring.
Stay connected with the latest in federal cannabis compliance! For tailored updates, compliance checklists, and regulatory alerts, trust CannabisRegulations.ai—your partner in navigating the evolving FDA Human Foods Program CBD 2025 landscape.